• Mashup Score: 48

    Long-term obesity was associated with markers of accelerated biological aging in adults aged 28-31 years, according to a multiple-events, case-control study published in JAMA Network Open. Investigators Paulina Correa-Burrows, PhD, et al., separated 205 Chilean adults (mean age, 29 years; 49% women) from the Santiago Longitudinal Study into three groups: healthy BMI across life course (Group 1; n=89; 43%), persistent obesity since adolescence (Group 2; n=43; 21%; mean obesity duration, 12.9 years) and

    Tweet Tweets with this article
    • Long-term obesity was associated with markers of accelerated biological aging in adults aged 28-31 years. Read the journal scan to learn more: https://t.co/iBvW186zAw #CardioX

  • Mashup Score: 45

    Intravenous tenecteplase before endovascular thrombectomy improves functional independence among patients with acute ischemic stroke due to large-vessel occlusion (LVO) presenting within 4.5 hours vs. thrombectomy alone, according to new results from the BRIDGE-TNK randomized trial, published in The New England Journal of Medicine. In this open-label trial, Zhongming Qiu, MD, et al., randomly assigned 550 patients (median age 70 years; 42% women), who presented to 39 hospitals in China within 4.5 hours

    Tweet Tweets with this article
    • BRIDGE-TNK: Intravenous tenecteplase before endovascular thrombectomy improves functional independence among patients with acute ischemic stroke due to large-vessel occlusion (LVO) presenting within 4.5 hours vs. thrombectomy alone. Learn more: https://t.co/28EZoj1mbY #CardioX

  • Mashup Score: 16

    The health of children in the U.S. has worsened over the past 17 years, across multiple domains, including child mortality, chronic conditions, obesity, functional status and symptoms, according to a recent study published in JAMA. Investigators Christopher B. Forrest, MD, PhD, et al., pooled data from five nationally representative surveys, 10 pediatric health systems (PEDSnet) and 18 comparator high-income nations (through the Organization for Economic Co-Operation and Development) to study child and

    Tweet Tweets with this article
    • The health of children in the U.S. has worsened over the past 17 years, across multiple domains, including child mortality, chronic conditions, obesity, functional status and symptoms. Learn more: https://t.co/byUPITjaKo #CardioX

  • Mashup Score: 32

    Tirzepatide leads to significantly greater loss of weight and weight circumference compared with semaglutide among adults with obesity but without diabetes, according to new results from the SURMOUNT-5 phase 3b trial, published in The New England Journal of Medicine. Louis J. Aronne, MD, et al., randomly assigned 751 patients (mean age 45 years) to receive the maximum tolerated dose of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly across 32 sites in the

    Tweet Tweets with this article
    • Tirzepatide leads to significantly greater loss of weight and weight circumference compared with semaglutide among adults with obesity but without diabetes, according to new results from the SURMOUNT-5 phase 3b trial. Learn more: https://t.co/HLoDIM6Tw1 #CardioX

  • Mashup Score: 45

    Among persons with chronic kidney disease (CKD) and type 2 diabetes (T2D), combination therapy with finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio (UACR) than either drug alone, according to results from the CONFIDENCE trial published June 5 in the New England Journal of Medicine. In this double-blind multicenter trial, Rajiv Agarwal, MD, FACC, et al., randomized 800 patients (mean age 66 years, 25% women) to receive 10 or 20 mg of finerenon e once

    Tweet Tweets with this article
    • CONFIDENCE trial results: Among persons w/ chronic kidney disease & type 2 diabetes, combination therapy w/ finerenone ➕ empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Learn more: https://t.co/kvUbR2tT3H #CardioX

  • Mashup Score: 8

    Two recent studies focus on the cardiovascular benefits of weight loss in middle age and the importance of effective weight loss maintenance (WLM). In t he first study, published in JAMA Network Open, investigators found that sustained weight loss in middle age compared to persistent overweight led to a long-term decreased risk of chronic disease, including type 2 diabetes, myocardial infarction, stroke, cancer, asthma or chronic obstructive pulmonary disease, and all-cause mortality. Timo E. Strandberg,

    Tweet Tweets with this article
    • In a recent study, investigators found that sustained weight loss in middle age compared to persistent overweight led to a long-term decreased risk of chronic disease and all-cause mortality. Read the journal scan to learn more: https://t.co/gtUnryAbVU #CardioX

  • Mashup Score: 24

    A fixed-dose combination therapy of obicetrapib plus ezetimibe was found to significantly reduce LDL-C in patients with preexisting or at high risk for developing atherosclerotic cardiovascular disease (ASCVD), according to results from the randomized, double-blind TANDEM trial published May 7 in The Lancet. Ashish Sarraju, MD, FACC, et al., included 407 participants (median age 68.0 years, 48% women) with preexisiting or high risk of ASCVD or heterozygous familial hypercholesterolemia from 48 centers in

    Tweet Tweets with this article
    • The BROADWAY trial assesses the safety and efficacy of obicetrapib among patients at high risk for cardiovascular events. Get more details ➡️ https://t.co/GPfRBQpxq6 #CardioX